Based on the datasets from the ONCOMINE platform, the mRNA levels of HLA-G were significantly elevated in 78.2% tumors (68 analyses showing higher expression vs. 19 analyses showing lower expression), especially in testicular embryonal carcinoma (fold change=8.262 and P=0.003), clear cell renal cell carcinoma (fold change=8.072 and P=6.44E-5), melanoma (fold change=7.974 and P=3.31E-5), pancreatic adenocarcinoma (fold change=6.739 and P=0.002), and glioblastoma (fold change=6.592 and P=8.80E-18) (Supporting Information Supplementary Table 1) (31–67). This evidence concerns the gene HLA-G and glioblastoma.